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 Notes & Additional 
Reading 
Summary and Key Points  
1. Adenocarcinoma of the endometrium is the most common 
gynecologic malignancy in the United States. 
 
2. Because abnormal vaginal bleeding is a common initial 
symptom of endometrial cancer, most cancers are discovered 
at an early stage. 
3. Endometrial adenocarcinoma is associated with a variety of 
risk factors, many of which are marked by a state of elevated 
or prolonged exposure to estrogens. 
 
4. Lower grade, or Type 1, endometrial cancers are most strongly 
associated with excessive estrogen exposure. 
 
5. Higher grade, or Type 2, endometrial cancers have a greater 
risk of relapse or systemic spread than Type 1 tumors. 
 
6. Surgical resection, a hysterectomy and removal of the ovaries 
plus/minus pelvic and paraaortic lymphadenectomy, is the 
foundation of treatment of endometrial cancer. Patients at high 
risk for local/regional recurrence receive adjuvant 
radiotherapy. Medically inoperable patients receive primary 
radiotherapy and or hormonal therapy. 
  
7. Sarcomas of the uterus also occur, but are uncommon. 
Leiomyosarcomas are aggressive tumors, and endometrial 
stromal sarcomas are likely to behave in an indolent fashion. 
 
8. Serous and clear cell carcinomas are rare but aggressive type 
of endometrial cancer. 
 
  
Epidemiology  
Endometrial adenocarcinoma is the most common gynecologic 
malignancy in the United States and the fourth most common 
malignancy in women overall. The American Cancer Society (ACS) 
data for endometrial cancer in the United States estimates that more 
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than 46,000 new cases occurred in 2011.1 Endometrial cancer causes 
approximately 7,310 deaths each year, and is the eighth leading site 
of cancer related deaths among American women.2 
Risk Factors 
Risk factors are well described for this cancer, and knowledge of 
these risk factors can contribute to early diagnosis and treatment. 
Many of these risks are conditions causing elevated estrogen 
levels or unusual duration of estrogen exposure, particularly 
unopposed estrogen exposure. These include polycystic ovary 
disease, granulosa cell tumor (benign estrogen producing tumor), 
nulliparity, infertility, which is associated with anovulatory 
cycles, prolonged unopposed post-menopausal hormone use, 
early menarche and late menopause, greater than 2 years 
of Tamoxifen use and obesity. Other factors increasing risk 
include being over 50, of white race and having diabetes mellitus, 
hypertension, cholecystitis, and thyroid disease. 
Surprisingly, intentional weight loss does not appear to be 
associated with decreased risk. On the other hand, regular physical 
exercise does appear to be associated with a decreased risk. Parity 
also decreases risk of endometrial cancer, as does extended 
lactation; breastfeeding longer than 18 months decreases risk by 
20%. Of course, hysterectomy prevents endometrial cancer except 
the rare case of endometrial cancer arising in endometriosis, which 
can occur many years after hysterectomy.3 
Diagnosis 
Clinically, most women with endometrial adenocarcinoma present 
with vaginal bleeding and discharge. Although postmenopausal 
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bleeding can be due to several benign etiologies such as 
endometrial atrophy, endometrial polyps, submucosal fibroids and 
endometrial hyperplasia, it should always be worked-up to exclude 
the possibility of endometrial adenocarcinoma. Pelvic ultrasound is 
the imaging modality of choice for the initial evaluation of the 
endometrium in patients presenting with postmenopausal bleeding, 
as well as women with risk factors for endometrial cancer presenting 
with menstrual cycle irregularities or heavy menstrual bleeding. The 
endometrial thickness on transvaginal ultrasound must always be 
correlated with the patient’s age and the stage of the menstrual 
cycle. In women with active menstrual cycle the endometrial 
thickness can reach up to 14 mm. In a postmenopausal patient, 
endometrial thickness less than 4 mm on transvaginal US generally 
excludes endometrial cancer 4; any abnormal endometrial thickness 
should be further investigated by hysteroscopy and/or endometrial 
biopsy. (Figure 1).  
  
 
 
Figure 1. 54-year-old female patient presenting with postmenopausal 
vaginal bleeding. Sagittal image from a transvaginal ultrasound reveals a 
thickened endometrium measured at 1.61 cm (between calipers). The 
myometrium is normal. Biopsy confirmed endometrial carcinoma. Courtesy 
of University of Massachusetts Medical School, Abdominal Imaging 
Division, UMass Memorial Medical Center. 
 
  
Almost 3/4ths of endometrial adenocarcinomas are Stage I when 
diagnosed. These women have an excellent prognosis. Only about 
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3% of these cancers are Stage IV at diagnosis. In addition to 
personal and clinical factors, there are two other entities that 
contribute to the epidemiology of endometrial cancer: genetic risk 
and atypical endometrial hyperplasia. 
  
Genetic risk for endometrial adenocarcinoma: The most common 
manifestation of hereditary nonpolyposis colorectal cancer (Lynch 
Syndrome) in women is endometrial cancer (40--‐60% lifetime risk) 
followed by colon cancer and then ovarian cancer. Individuals from 
these families are at risk of many other cancers, including stomach, 
pancreas, kidney/ureter, hepatobiliary tract, prostate, ovaries, gall 
bladder duct, brain, small intestine, breast and the skin.5 
 
Atypical endometrial hyperplasia is considered a precursor lesion to 
endometrial cancer. Endometrial hyperplasia occurs as a continuum 
from simple to complex (Figure 2), and may progress to an invasive 
endometrial cancer if left untreated.6 Atypical endometrial hyperplasia 
is usually treated with a hysterectomy, unless a woman desires 
childbearing in which case progestin therapy and close monitoring is 
offered. When childbearing is completed a hysterectomy is usually 
recommended.7 
 
  
 
 
Figure 2. This image shows mostly endometrial complex hyperplasia with 
only few foci of well differentiated adenocarcinoma, endometrioid type. The 
hyperplastic glands are tightly crowded, but still separate from each other by 
a very thin strand of stromal tissue. In the adenocarcinoma foci we start 
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observing glands within glands and areas showing cribriforming pattern of 
growth. Courtesy of University of Massachusetts Medical School, Abdominal 
Imaging Division, UMass Memorial Medical Center. 
  
Histological Types Of Endometrial Cancer  
Cancers of the uterus originate from either (1) the endometrium, or 
lining of the uterus, and are called carcinomas or (2) the uterine 
muscle or connective tissues which are called sarcomas. 
 
  
The most common histological type of endometrial carcinoma is the 
adenocarcinoma, which arises from the glandular lining of the uterus. 
Eighty percent (80%) of endometrial adenocarcinomas are the 
endometrioid type and consist of glandular cells that resemble those 
of the uterine lining. (Figures 3 & 4). If the adenocarcinoma contains 
squamous cells it is called an adenocarcinoma with squamous 
differentiation. (Figure 5). The grade of the cancer is determined by 
the grade of the adenomatous component. 
 
  
 
 
Figure 3. Endometrioid Adenocarcinoma, Grade 1. This grade endometrioid 
adenocarcinoma shows villoglandular growth pattern. The tumor superficially 
invades into the underlying myometrium. Courtesy of University of 
Massachusetts Medical School, Department of Pathology, UMass Memorial 
Medical Center. 
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Figure 4. Endometrioid Adenocarcinoma with Myometrial Invasion, Grade 2. 
A section taken from the endometrial mass shows many neoplastic glands 
invade deep into the myometrium. Because these glands resemble normal 
proliferative endometrial glands, this type of cancer is called endometrioid 
type. On the other hand, these glands are malignant, not benign, mainly 
because of their complex architecture and infiltrating growth pattern. 
Endometrioid adenocarcinoma is the most common type of endometrial 
carcinoma. It is estrogen-dependent, which is also known as “type I” 
endometrial cancer. Courtesy of University of Massachusetts Medical School, 
Department of Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 5. In the center, a focus of squamous metaplasia is present. Such 
areas are discounted when the percentage of the solid component of the 
adenocarcinoma is estimated for tumor grading purposes. Courtesy of 
University of Massachusetts Medical School, Department of Pathology, 
UMass Memorial Medical Center. 
 
  
The remaining non-endometrioid endometrial adenocarcinomas are 
the clear-cell carcinoma (Figure 6), serous carcinoma (also called 
papillary serous carcinoma) (Figures 7 & 8), and poorly differentiated 
carcinoma. 
 
  
Endometrial Cancer 
Richard S. Pieters, MD 
Maryanne Bombaugh, MD  
Yuxin Liu, MD, PhD 
Gina Cunto-Amesty, MD 
Adib R. Karam, MD 
Elizabeth Kurian, MD  
Sarah Hughes, MD 
 
 
7 
Cancer Concepts: A Guidebook for the Non-Oncologist- Endometrial Cancer 
08 December 2014 
 
 
Figure 6. Clear cell carcinoma: Type II tumor. Patients tend to be older than 
those with endometrioid adenocarcinoma. These are biologically aggressive 
tumors with a worse prognosis than endometrioid adenocarcinoma. Courtesy 
of University of Massachusetts Medical School, Department of Pathology, 
UMass Memorial Medical Center. 
 
  
 
 
Figure 7. Uterine Serous Carcinoma. Type II endometrial cancer is estrogen-
independent. An example is endometrial serous carcinoma. Endometrial 
serous carcinoma is composed of highly malignant cells growing around a 
fibrovascular core. Numerous mitoses are present. This is a highly 
aggressive endometrial cancer and commonly seen in elderly patients. 
Courtesy of University of Massachusetts Medical School, Department of 
Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 8. Uterine serous carcinoma. Courtesy of University of Massachusetts 
Medical School, Department of Pathology, UMass Memorial Medical Center. 
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There is one tumor of the endometrium with unique cancer 
morphology, with features of both an endometrial carcinoma and a 
sarcoma. This tumor is called a uterine carcinosarcoma (Figures 9 & 
10), also known as a malignant mixed Mullerian tumor. Although 
typically classified as a uterine sarcoma, it is thought that this tumor 
may actually be a form of poorly differentiated carcinoma because the 
carcinosarcoma and endometrial carcinomas are similar in how they 
are treated and how they spread. CS is an aggressive tumor, similar 
to or worse than Grade 3 adenocarcinoma with the same extent of 
disease. 
 
  
 
 
Figure 9. Uterine Carcinosarcoma. Courtesy of University of Massachusetts 
Medical School, Department of Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 10. Uterine Carcinosarcoma. Carcinosarcoma is a biphasic tumor 
including carcinoma and sarcoma component. The sarcoma component can 
be leiomyomsarcoma, stromal sarcoma, or undifferentiated sarcoma. Some 
cases have bone and cartilage component (left lower corner). Courtesy of 
University of Massachusetts Medical School, Department of Pathology, 
UMass Memorial Medical Center. 
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Endometrial Carcinoma Grading  
The grading of this cancer is done on a scale of 1 to 3 based on the 
amount of solid growth and nuclear atypia present. 
 
  
Endometrial Carcinoma Prognostic Typing  
Endometrial cancers are often further categorized, based on 
underlying causes and prognosis, into a Type 1 or Type 2 cancer. 
 
  
Type 1 is thought to be caused by excess estrogen, is usually not 
aggressive and is slow to metastasize or spread to contiguous 
tissues. Grade 1 (Figure 11) and Grade 2 endometrioid cancers 
(Figure 12) are examples of Type 1 endometrial cancers. 
 
  
 
 
Figure 11. The well differentiated adenocarcinoma of the endometrium 
(endometrioid type, FIGO grade 1) typically has a similarity to the benign 
endometrial tissue, in the sense that the neoplastic epithelium still attempts 
to organize in glandular structures that resemble normal endometrial glands. 
Courtesy of University of Massachusetts Medical School, Department of 
Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 12. (Figure 12A) FIGO Grade 2. Notice that this neoplasm still has  
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glandular structures, but in some areas, these glands start getting confluent 
and form solid areas. (Figure 12B) FIGO Grade 3. Notice the almost 
complete lack of gland-like structures and the monotonous sheet of 
malignant cells. It is difficult to identify the tissue of origin. Therefore it is a 
poorly differentiated carcinoma. A FIGO grade 1 tumor has less than 5 % 
solid areas, FIGO grade 2, between 6 to 50 % of solid areas and FIGO grade 
3, more than 50 % of solid areas. Courtesy of University of Massachusetts 
Medical School, Department of Pathology, UMass Memorial Medical Center 
  
Type 2 endometrial cancers do not appear to be caused by estrogen 
excess, and they are more likely to be aggressive, metastasize, and 
have unfavorable prognoses. Serous carcinoma, poorly differentiated 
carcinoma and Grade 3 endometrioid carcinoma would be considered 
Type 2. Higher grade endometrioid tumors and non-endometrioid 
endometrial carcinomas (Type 2) are associated with higher rates of 
deep myometrial invasion and lymphatic spread.8 
 
  
Uterine Sarcomas  
Sarcomas comprise about 3% of uterine cancers. Technically, they 
are NOT endometrial cancers, since they arise from the myometrial 
wall. They also often present with abnormal uterine bleeding, but 
some tumors are found because of pelvic masses. Leiomyomas 
(fibroids) (Figure 13) are quite common, completely benign (Figure 14) 
and often resected if symptomatic (Figure 15). 
 
  
 
 
Figure 13. Uterine Leiomyomata. Leiomyoma (uterine fibroid) is a benign 
smooth muscle tumor. As shown in this photograph, leiomyoma is round, 
white, and firm nodule. The cut surface has a whorled appearance. The 
nodules are located at subserosal, intramural, or submucosal. Even a very 
 
Endometrial Cancer 
Richard S. Pieters, MD 
Maryanne Bombaugh, MD  
Yuxin Liu, MD, PhD 
Gina Cunto-Amesty, MD 
Adib R. Karam, MD 
Elizabeth Kurian, MD  
Sarah Hughes, MD 
 
 
11 
Cancer Concepts: A Guidebook for the Non-Oncologist- Endometrial Cancer 
08 December 2014 
small submucosal leiomyoma can cause heavy bleeding due to compression 
of the endometrium. As seen in this case, the endometrial cavity is severely 
deformed by multiple leiomyomata. Courtesy of University of Massachusetts 
Medical School, Department of Pathology, UMass Memorial Medical Center. 
  
 
 
Figure 14. As seen in this H&E slide, leiomyoma is composed of spindle cells 
arranged in fascicles. The spindle cells have cigar-shaped nuclei and 
eosinophilic cytoplasm. These spindle cells are smooth muscle cells. 
Leiomyoma is the most common benign uterine neoplasm. The malignant 
counterpart is leiomyosarcoma which displays highly atypical spindle cells, 
necrosis, and extremely high mitotic activity. An example of leiomyosarcoma 
is shown in the next slide. However the classification of uterine smooth 
muscle tumor is very complicated. Some leiomyomas may display certain 
“atypical features”, such as high mitotic activity or cytological atypia. These 
are known as “atypical leiomyoma” or STUMP (Smooth Muscle Tumors of 
Uncertain Malignant Potential). As the name indicated, it is difficult to predict 
these tumors’ behavior and they may follow a benign or a malignant course. 
Courtesy of University of Massachusetts Medical School, Department of 
Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 15. 49-year-old female patient with history of uterine fibroids. Coronal 
plane (a) and sagittal plane (b) images from pelvic MRI, demonstrate multiple 
uterine fibroids that were stable over four years. Courtesy of University of 
Massachusetts Medical School, Abdominal Imaging Division, UMass 
Memorial Medical Center. 
 
  
But sometimes the surgeon and the patient are surprised and the  
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tumors are malignant (Figure 16). Leiomyosarcomas are the most 
common and most aggressive myometrial sarcomas, even in early 
stage (Figures 17 & 18). Endometrial stromal cell sarcomas have an 
indolent course, tend to present as Stage I, occur in younger women, 
and preservation of ovaries does not alter prognosis. The mainstay of 
treatment for both is surgery, which can be conservative and spare 
ovaries in young women; limited resections of uterine sarcomas with 
preservation of fertility have been reported. For locally advanced 
leiomyosarcomas, survival appears to be improved with adjuvant 
radiotherapy. As with other sarcomas, the lungs are the most common 
site of metastasis. Removal of oligometastic disease can be 
associated with long term survival.9 
  
 
 
Figure 16. Uterine leiomyosarcoma. As seen in this gross picture, the uterus 
is deformed by a large, fresh, solid mass (8 cm in diameter). Areas of 
hemorrhage and necrosis are seen on the cut section. Courtesy of University 
of Massachusetts Medical School, Department of Pathology, UMass 
Memorial Medical Center. 
 
  
 
 
Figure 17. Compared with leiomyoma, the present tumor is highly cellular on 
a low power view. Courtesy of University of Massachusetts Medical School, 
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Department of Pathology, UMass Memorial Medical Center. 
  
 
 
Figure 18. On high power view, the tumor is composed of highly atypical 
spindle cells with hyperchromatic nuclei. Numerous mitoses are seen. This is 
diagnostic for malignant smooth muscle tumor: leiomyosarcoma. Courtesy of 
University of Massachusetts Medical School, Department of Pathology, 
UMass Memorial Medical Center. 
 
  
Management of Endometrial Cancer  
Watch the first two and last two minutes of this YouTube movie 
(https://www.youtube.com/watch?v=xHHR8oxuo1M) of a robotic 
laparoscopic hysterectomy. 
 
  
Once a diagnosis of endometrial cancer has been made through 
endometrial tissue sampling, conventional therapy begins with 
surgical staging that includes the removal of the uterus (including 
cervix) (Figure 19), fallopian tubes, and ovaries; peritoneal cytology; 
and intraoperative assessment of the pelvic and para--‐aortic lymph 
nodes. In select circumstances, such as when there is bulky cervical 
disease or if a patient cannot safely undergo surgery, radiation 
therapy may be given preoperatively or as the primary treatment to 
treat disease and control bleeding. Low grade, low volume disease 
patients may be treated with brachytherapy alone; larger volume 
disease and higher grade, with significant risk of nodal disease is 
usually treated with external beam treatment of the uterus and pelvic 
lymph nodes, followed by brachytherapy (Figures 20-23). (See 
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Principles of Radiation Oncology chapter). Patients with significant 
medical co--‐morbidities or with low grade/low stage endometrial 
cancer may be treated with external beam or even hormonal 
suppression alone. 
  
 
 
Figure 19. The uterus is opened to show the endometrial cavity. There is a 
mass lesion arising from the posterior endometrium and protruding into the 
uterine cavity. This is endometrial adenocarcinoma. The remaining 
endometrium is very thin and most likely benign. The myometrium and 
cervix are normal. Courtesy of University of Massachusetts Medical School, 
Department of Pathology, UMass Memorial Medical Center. 
 
  
 
 
Figure 20 Brachytherapy. Uterine capsules, loaded with radioactive iridium 
for treatment of endometrial cancer. These are placed through the cervix to 
attempt to push dose out into the cornua of the cavity.  
20a. Axial CT slice (arrows point at capsules), 20b. 3 dimensional treatment 
plan dose cloud, showing rapid fall off from sources within capsules. 20c. 
Coronal CT slice, (arrows point at capsules) 20d. Sagittal CT slice. Courtesy 
of University of Massachusetts Medical School, Department of Radiation 
Oncology, UMass Memorial Medical Center. 
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Figure 21. Endometrial Cancer High Dose Rate Applicator Tandems 
geometry is fixed to push tips into cornua 20b Dose volume Histogram 
(DVH) showing very rapid dose falloff from applicator, which protects 
surrounding normal structures. Courtesy of University of Massachusetts 
Medical School, Department of Radiation Oncology, UMass Memorial 
Medical Center. 
 
  
 
 
Figure 22. Fletcher Suit Delclos Uterine Low Dose Rate applicator. Loaded 
with radioactive cesium sources. Applicator is held in place by vaginal 
packing. Patient must remain in bed for 2-3 days while treatment is 
administered, usually twice, 1 week apart. Tandem is tube in uterus, ovoids 
are cylinders next to tandem, which are placed in vaginal fornices, with 
cervix wedged between. Dose is pushed out into uterine cavity cornua by 
loading a stronger source in the tip of the tandem. With this application, 
deviated to the left, the left side will receive more dose than the right. 
Courtesy of University of Massachusetts Medical School, Department of 
Radiation Oncology, UMass Memorial Medical Center. 
 
  
 
 
Figure 23. Brachytherapy: HDR Tandem and Ovoids. DVH demonstrates  
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less rapid dose falloff than is seen with capsule treatment seen in figure 20, 
an effect of multiple source positions in ovoids. Notice pear shaped dose 
distribution in coronal view (22c) Yellow lines represent 100% of prescription 
dose. Arrows point at vaginal packing. Courtesy of University of 
Massachusetts Medical School, Department of Radiation Oncology, UMass 
Memorial Medical Center. 
  
 
 
Figure 24. External Beam Fields– treatment volume inside inner yellow 
lines. 24a. AP pelvis field. PA field is opposed for a 4 field plan (see figure 
25) 24b. Right Lateral Pelvis field with uterus in red. 24c. Left Lateral Pelvis 
field without uterus to show position of femoral heads in field. Courtesy of 
University of Massachusetts Medical School, Department of Radiation 
Oncology, UMass Memorial Medical Center. 
 
  
 
 
Figure 25. External beam plan, 4 field pelvis. Dose comes from AP, PA & 
Right and Left Lateral fields, or beam. A single axial slice, called a 2D plan. 
Courtesy of University of Massachusetts Medical School, Department of 
Radiation Oncology, UMass Memorial Medical Center. 
 
  
In patients who have confirmed deep myometrial invasion (Figure 
26), cervical stromal involvement, pelvic nodal or vaginal metastases, 
or high grade cancer after surgical staging, adjuvant therapy is 
usually recommended to attempt to prevent disease recurrence. 
Adjuvant therapy may be delivered with external beam radiotherapy 
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or vaginal brachytherapy. For node positive, high grade tumors, the 
addition of chemotherapy to adjuvant radiotherapy is under active 
investigation.10 
  
 
 
Figure 26. 51-year-old female patient with biopsy proven endometrial 
carcinoma. Coronal plane at the level of the uterine fundus (a) and mid-
sagittal plane (b) images from pelvic MRI demonstrate a large and 
heterogeneous endometrial mass consistent with the biopsy proven 
endometrial carcinoma, extending into the endocervical canal. Note the 
presence of deep myometrial invasion at the level of the fundus (a). 
Courtesy of University of Massachusetts Medical School, Abdominal 
Imaging Division, UMass Memorial Medical Center 
 
  
Prognosis  
With modern treatment, about 90 % of patients with Stage I 80% with 
Stage II, 65% with Stage III, and 25% of Stage IV adenocarcinoma of 
the endometrium will be alive at 5 years. Older patients and patients 
with higher grade tumors will do less well, as will CS patients, stage 
for stage. Endometrial stromal sarcomas have an excellent 5 year 
survival.11 Median survival for leiomyosarcomas is about 4 years.12 
 
  
Conclusion  
Endometrial adenocarcinoma is common. Postmenopausal vaginal 
bleeding is never normal and patients experiencing it must be 
worked up for endometrial cancer. Most patients present with early 
stage disease which is estrogen dependent, or Type 1, and have an 
excellent prognosis. Uterine sarcomas are much less common. 
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Leiomyosarcomas, carcinosarcomas and Type 2 endometrial 
cancers are more aggressive cancers and have a poorer prognosis. 
Stages of endometrial cancer according to FIGO (International 
Federation of Gynecology and Obstetrics classification in brief).8 
Stage 1 Tumor confined to the uterus 
Stage 2 Tumor extends to the cervix 
Stage 3 
Tumor extends to the adjacent organs but not the 
bladder and rectal mucosa or involves the regional 
lymph nodes 
Stage 4 Tumor metastasize to the distant organs 
Thought Questions 
1. Estrogen can increase the risk of endometrial cancer,
particularly Type 1 tumors. Tamoxifen, a selective estrogen 
receptor modulator, lowers a post-menopausal woman’s risk 
of developing an estrogen receptor positive breast cancer by 
40%, but increases the risk of developing endometrial cancer 
by 300%. Think of ways that Tamoxifen can reduce the risk of 
an estrogen-associated cancer in one organ, but increase the 
risk in another. 
Expert Answer 
Your answer: 
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2. Endometrial cancer is the most common gynecologic cancer 
in the United States, but cervical cancer is the most common 
gynecological cancer in many developing countries. What 
reasons may contribute to differences in incidence of these 
cancers in different societies? 
Expert Answer 
Your answer:  
  
  
  
  
  
  
  
  
  
  
  
  
3. Why is it believed that the incidence of endometrial cancer will 
increase in the future? 
Expert Answer 
Your answer:  
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Glossary 
Cribriforming pattern- A sieve like histologic appearance 
 
Nulliparity- The state of never having been pregnant  
Polycystic ovary disease (Stein-Leventhal Syndrome)- An endocrine 
disorder with enlarged ovaries with small collections of fluid, follicles- 
best seen on ultrasound or CT, associated with infrequent or 
prolonged menses, infertility, excess hair growth, acne, and obesity. 
 
Unopposed estrogen exposure– Estrogen exposure without 
progesterone exposure 
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